Beijing Kawin Technology Share-Holding Co. Ltd

Ten years of qualification Audited Supplier

Ten years of qualification Audited Supplier

Company Profile
  • Year Established: 2008
  • Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Reputation,Quality Service
  • Business Type: Manufacturer
  • R&D Capacity: Own Brand
  • Main Sales Markets : Central/South America,Eastern Europe,Asia,Middle East,Africa

Beijing Kawin Technology Share-Holding Co., Ltd. (Kawin Technology) is located in the Beijing Economy-Technology Development Area (BDA), also well known as the "Pharmaceutical Valley". Based on biotechnology platforms, Kawin Technology is committed to become a biopharmaceutical company that provides the treatment solutions to viral disease for our patients. Since establishment, Kawin Technology has formed strategic partnership with Legend Capital, Haitong Capital and Cybernaut respectively. Kawin Technology is a High & New Technology Enterprise certified by Beijing Municipal Science & Technology Commission. It has also been listed as one of Hundred Pilot Enterprises and Top 100 Most-promising Enterprises by Zhongguancun Technology Park. Kawin Technology has a rapidly-growing R&D team, mainly composed of overseas returnee experts and local talents with doctor or master degrees. Recognized as “Beijing Engineering Research Center for Recombinant Protein Drugs”, our R&D center is striving to develop a series of new medicines through integrated innovation as well as collaborations from the national research projects, such as the “11th Five-Year Plan” and “12th Five-Year Plan”.  Kawin Technology has 7 GMP production workshops, with rich pharmaceutical dosage production lines: biological products production line includes 3 dosage forms of small volume injection (non final sterilization), freeze-dried powder injection and effervescent tablets; chemical products production line includes 4 dosage forms of small volume injection (final sterilization and non final sterilization), freeze-dried powder injection, tablet and capsule. Among them, the chemical final sterilization injection production line has passed the Ukrainian international GMP certification (PIC / s standard). Kawin Technology has established a nationwide marketing network, among which the top products: Recombinant Human Interferon α2b injection, Compound Glycyrrhizin Capsules, Recombinant Human Interferon α2b Vaginal Effervescent Tablets  are in the top market share. The products have been exported to Philippines, Pakistan, Vietnam and other countries, and registered in Colombia, Indonesia and other countries. “Innovation for a better life”! Kawin Technology is becoming a leading pharmaceutical brand in viral disease and making every effort to improve the wellbeing of human beings.

Year Established: 2008

Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Reputation,Quality Service

Business Type: Manufacturer

R&D Capacity: Own Brand

Main Sales Markets : Central/South America,Eastern Europe,Asia,Middle East,Africa

Top Products
Copyright 2006-2020 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 沪ICP备05034851号-182
Powered by